Chest Medicine
Small RCT: Inhaled budesonide reduces the need for hospitalization in COVID-19 patients
11 Feb, 2021 | 02:18h | UTCCommentaries: Common asthma treatment reduces need for hospitalisation in COVID-19 patients, study suggests – University of Oxford AND Expert reaction to preprint on an RCT of inhaled budesonide in the treatment of early COVID-19 – Science Media Centre
WHO experts recommend AstraZeneca COVID vaccine across all ages and countries
11 Feb, 2021 | 02:20h | UTCCommentaries: WHO Experts Recommend AstraZeneca COVID Vaccine Across All Ages & Countries – Signal For Start Of Global COVAX Vaccine Rollout – Health Policy Watch AND WHO backs use of Oxford/AstraZeneca Covid vaccine for adults of all ages – The Guardian AND Covid: WHO backs Oxford vaccine ‘even if variants present’ – BBC AND Expert reaction to WHO recommending use of the Oxford/AstraZeneca COVID-19 vaccine, including in over 65s – Science Media Centre AND Up Against Mutants, WHO Says AstraZeneca Vaccine Is Still A Good Bet – NPR
ACP: Update on Remdesivir use for hospitalized COVID-19 patients
11 Feb, 2021 | 02:15h | UTC
Perspective: Leave your antibodies alone
11 Feb, 2021 | 02:12h | UTCLeave Your Antibodies Alone – The Atlantic
Rapid coronavirus tests: a guide for the perplexed
10 Feb, 2021 | 01:52h | UTCRapid coronavirus tests: a guide for the perplexed – Nature
Put to the test: use of rapid testing technologies for covid-19
10 Feb, 2021 | 01:51h | UTCPut to the test: use of rapid testing technologies for covid-19 – The BMJ
Covid-19: Four in 10 people with evidence of past infection had no classic symptoms, study finds
10 Feb, 2021 | 01:48h | UTC
Variant-proof vaccines — invest now for the next pandemic
9 Feb, 2021 | 01:39h | UTCVariant-proof vaccines — invest now for the next pandemic – Nature
Thrombosis and COVID-19: Controversies and (Tentative) Conclusions
9 Feb, 2021 | 01:41h | UTCThrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases
Commentary on Twitter
https://twitter.com/JohnRossMD/status/1357992429824081921
Small RCT: Peginterferon lambda increases viral clearance in outpatients with COVID-19
9 Feb, 2021 | 01:36h | UTC
Coronavirus vaccine strategy needs rethink after resistant variants emerge, say scientists
9 Feb, 2021 | 01:38h | UTCRelated: South Africa halts AstraZeneca vaccine rollout over new variant – BBC AND ‘What other variants might be out there?’ An expert on viral evolution on what’s happening with coronavirus mutations – STAT AND Covid-19: Oxford vaccine offers less protection against South Africa variant (study and commentaries) AND South Africa suspends use of AstraZeneca’s COVID-19 vaccine after it fails to clearly stop virus variant – Science
Does taking Vitamin D prevent or treat COVID-19?
9 Feb, 2021 | 01:20h | UTCDoes Taking Vitamin D Prevent or Treat COVID-19? – HIV and ID Observations
ARDS: Contemporary management and novel approaches during COVID-19
9 Feb, 2021 | 01:31h | UTC
Commentary on Twitter
Review Article: Acute Respiratory Distress Syndrome #ARDS: Contemporary Management and Novel Approaches during #COVID19 https://t.co/Hbsuejegos pic.twitter.com/9rOyZmOWpA
— Anesthesiology (@_Anesthesiology) February 5, 2021
RCT: Posaconazole noninferior to voriconazole for primary treatment of invasive aspergillosis
7 Feb, 2021 | 21:00h | UTCPosaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
[Press release – not published yet] Sinovac Announces Phase III Results of Its COVID-19 Vaccine
7 Feb, 2021 | 21:29h | UTCSinovac Announces Phase III Results of Its COVID-19 Vaccine
Commentaries: Expert reaction to announcement of results of phase III of Sinovac vaccine in China – Science Media Centre AND Sinovac says COVID-19 vaccine effective in preventing hospitalization, death – Reuters
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1357856593392463874
[Press release – not published yet] Covid-19: Oxford vaccine offers less protection against South Africa variant
7 Feb, 2021 | 21:25h | UTCOxford Covid-19 vaccine trial results – University of the Witwatersrand
Commentaries: Covid: Oxford jab offers less S Africa variant protection – BBC AND Expert reaction to news reports that the Oxford/AZ vaccine gives limited protection against mild disease caused by the South African variant of SARS-CoV-2 – Science Media Centre AND Oxford/AstraZeneca COVID shot less effective against South African variant: study – Reuters
Commentary on Twitter (thread – click for more)
[Thread] 1. NEW Early data (not yet peer reviewed) shows the #AstraZeneca #CovidVaccine, that SA will start to administer this month, doesn't appear to offer protection against mild/moderate disease caused by the #501YV2 variant identified in the country. https://t.co/UWD0Xilner
— Mia Malan (@miamalan) February 7, 2021
The good and the (potentially) bad: What scientists know about variants and Covid-19 vaccines
7 Feb, 2021 | 21:23h | UTCThe good and the (potentially) bad: What scientists know about variants and Covid-19 vaccines – STAT
See also: What Will it Take to Make Covid-19 Vaccines Variant-Proof? – Wired AND What’s Going On With All These Coronavirus Variants? An Illustrated Guide – NPR AND Video: Coronavirus Variants – What They Mean – JAMA
Cohort study: ECMO in patients with severe respiratory failure from COVID-19
7 Feb, 2021 | 21:16h | UTCRelated: ECMO for COVID-19 patients in Europe and Israel – Intensive Care Medicine
Commentaries on Twitter
#ECMO in #COVID19, multicenter US based study on 5122 critical adults
➡️#ECLS in 3.7%, 66.8% of whom survived to hospital discharge or 60 days
➡️considerably reduced mortality with early ECMO in severe hypoxemic respiratory failure vs conventional approachhttps://t.co/OgS7Q5tctS pic.twitter.com/PO5O8t3l8F— Intensive Care Medicine (@yourICM) February 4, 2021
Online today @yourICM, our important multicenter descriptive and trial emulation work around #ECMO and #COVID19 @BIDMCAnesthesia @DavidLeaf9 @SamanthaSkb273 @_MiguelHernan from the STOP-COVID Investigators https://t.co/DuhWufYqZ3 pic.twitter.com/nXPvKDYMYL
— Shaz Shaefi (@SShaefi) February 2, 2021
What’s the risk of dying from a fast-spreading COVID-19 variant?
7 Feb, 2021 | 21:21h | UTCWhat’s the risk of dying from a fast-spreading COVID-19 variant? – Nature
Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv
Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19
7 Feb, 2021 | 21:13h | UTC“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia
NIH Treatment Guideline Update: “there are insufficient data to recommend either for or against the use of tocilizumab or sarilumab for the treatment of COVID-19”
5 Feb, 2021 | 01:44h | UTC
Prevalence and trends in tobacco use among adolescents aged 13–15 years in 143 countries, 1999–2018: findings from the Global Youth Tobacco Surveys
4 Feb, 2021 | 01:20h | UTCPrevalence and trends in tobacco use among adolescents aged 13–15 years in 143 countries, 1999–2018: findings from the Global Youth Tobacco Surveys – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary on Twitter
NEW—Global Youth Tobacco Surveys data from 13–15-year-olds in 140 countries, suggests 40% of countries show no progress in reducing cigarette smoking in adolescents over the past 20 years. Read more findings from the @LancetChildAdol study: https://t.co/qlHzvHHdOD
— The Lancet (@TheLancet) February 3, 2021
Systematic review: Telerehabilitation for chronic respiratory disease
4 Feb, 2021 | 01:08h | UTCTelerehabilitation for chronic respiratory disease – Cochrane Library
UK Biobank study shows that COVID-19 antibodies remain for at least 6 months post-infection for the vast majority of people who have had the virus
4 Feb, 2021 | 01:32h | UTCCommentary: Covid: Antibodies last at least six months in most – BBC